Pub Date : 2015-01-01DOI: 10.2174/2210309005666150804195033
Metini Janyasupab, Ying-Hui Lee, Yuan Zhang, Chen W Liu, Jieyi Cai, Adriana Popa, Anna C Samia, Kuan W Wang, Jiaqiang Xu, Chi-Chang Hu, Michael K Wendt, Barbara J Schiemann, Cheryl L Thompson, Yun Yen, William P Schiemann, Chung C Liu
Metastasis accounts for 90% of the mortality associated with breast cancer. Upregulated expression of members of the lysyl oxidase (LOX) family of secreted copper amine oxidases catalyzes the crosslinking of collagens and elastin in the extracellular matrix. LOXs are linked to the development and metastatic progression of breast cancers. Accordingly, aberrant expression of LOX-like 2 (LOXL2) is observed in poorly differentiated, high-grade tumors and is predictive of diseases recurrence, and for decreased overall patient survival. Therefore, LOXL2 expression may serve as a biomarker for breast cancer. Mechanistically, hydrogen peroxide is produced as a byproduct of LOXL2 when using an appropriate substrate, lysine. We exploited this chemistry to generate a revolutionary gold-based electrochemical biosensor capable of accurately detecting nanomolar quantities of LOXL2 in mouse blood, and in human blood samples. Two different sources of the blood samples obtained from breast cancer patients were used in this study indicating the applicability of detecting LOXL2 in breast cancers patients. Limited numbers of urine specimens from breast cancer patients were also tested. Collectively, all of these tests show the promise and potential of this biosensor for detecting LOXL2 as a surrogate biomarker of breast cancer. This work is described in WO 052962 A1 (2014).
{"title":"Detection of Lysyl Oxidase-Like 2 (LOXL2), a Biomarker of Metastasis from Breast Cancers Using Human Blood Samples.","authors":"Metini Janyasupab, Ying-Hui Lee, Yuan Zhang, Chen W Liu, Jieyi Cai, Adriana Popa, Anna C Samia, Kuan W Wang, Jiaqiang Xu, Chi-Chang Hu, Michael K Wendt, Barbara J Schiemann, Cheryl L Thompson, Yun Yen, William P Schiemann, Chung C Liu","doi":"10.2174/2210309005666150804195033","DOIUrl":"https://doi.org/10.2174/2210309005666150804195033","url":null,"abstract":"<p><p>Metastasis accounts for 90% of the mortality associated with breast cancer. Upregulated expression of members of the lysyl oxidase (LOX) family of secreted copper amine oxidases catalyzes the crosslinking of collagens and elastin in the extracellular matrix. LOXs are linked to the development and metastatic progression of breast cancers. Accordingly, aberrant expression of LOX-like 2 (LOXL2) is observed in poorly differentiated, high-grade tumors and is predictive of diseases recurrence, and for decreased overall patient survival. Therefore, LOXL2 expression may serve as a biomarker for breast cancer. Mechanistically, hydrogen peroxide is produced as a byproduct of LOXL2 when using an appropriate substrate, lysine. We exploited this chemistry to generate a revolutionary gold-based electrochemical biosensor capable of accurately detecting nanomolar quantities of LOXL2 in mouse blood, and in human blood samples. Two different sources of the blood samples obtained from breast cancer patients were used in this study indicating the applicability of detecting LOXL2 in breast cancers patients. Limited numbers of urine specimens from breast cancer patients were also tested. Collectively, all of these tests show the promise and potential of this biosensor for detecting LOXL2 as a surrogate biomarker of breast cancer. This work is described in WO 052962 A1 (2014).</p>","PeriodicalId":74645,"journal":{"name":"Recent patents on biomarkers","volume":"5 2","pages":"93-100"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493150/pdf/nihms857765.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9932531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-09-01DOI: 10.2174/2210309011202030202
Ganesan Ramesh
Acute kidney injury (AKI) is a common problem in the hospital setting and intensive care unit. Despite improved understanding, there are no effective therapies available to treat AKI. AKI is often diagnosed late and, therefore, identification of a biomarker that will facilitate early diagnosis of AKI and provide a prognosis is desirable. The recent identification of a novel biomarker, netrin-1, that is capable of diagnosing early during the course of kidney injury has created much interest in this molecule. In this paper, we review recent progress made in understanding netrin-1 as a biomarker and therapeutic molecule for acute and chronic kidney diseases. We also discuss both the usefulness of netrin-1 as a biomarker of other diseases and as a possible therapeutic agent and relevant patents for inflammatory diseases.
{"title":"Role of Netrin-1 Beyond the Brain: From Biomarker of Tissue Injury to Therapy for Inflammatory Diseases.","authors":"Ganesan Ramesh","doi":"10.2174/2210309011202030202","DOIUrl":"https://doi.org/10.2174/2210309011202030202","url":null,"abstract":"<p><p>Acute kidney injury (AKI) is a common problem in the hospital setting and intensive care unit. Despite improved understanding, there are no effective therapies available to treat AKI. AKI is often diagnosed late and, therefore, identification of a biomarker that will facilitate early diagnosis of AKI and provide a prognosis is desirable. The recent identification of a novel biomarker, netrin-1, that is capable of diagnosing early during the course of kidney injury has created much interest in this molecule. In this paper, we review recent progress made in understanding netrin-1 as a biomarker and therapeutic molecule for acute and chronic kidney diseases. We also discuss both the usefulness of netrin-1 as a biomarker of other diseases and as a possible therapeutic agent and relevant patents for inflammatory diseases.</p>","PeriodicalId":74645,"journal":{"name":"Recent patents on biomarkers","volume":"2 3","pages":"202-208"},"PeriodicalIF":0.0,"publicationDate":"2012-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3517172/pdf/nihms415901.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31113551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Acute kidney injury (AKI) causes increased morbidity in critically ill children and damage to the kidney, a central mediator of homeostasis in the body, affects survival. The incidence of AKI in pediatrics is significant and despite alarming data, therapeutic interventions have failed to effect a meaningful difference in outcomes. In this review, we will discuss the epidemiology of AKI in pediatrics, treatment strategies attempted to date, experimental therapies targeting molecular patterns associated with AKI, and highlight the needed direction of AKI research and management. Prospective trials in pediatrics are needed to test the validity of diagnostic tools, to identify the point of most efficacious intervention, and to underscore the therapies that can be effective in the different downstream effects of AKI.
急性肾损伤(AKI)会增加重症儿童的发病率,而肾脏作为体内平衡的核心介质,其损伤会影响存活率。急性肾损伤在儿科的发病率很高,尽管数据令人震惊,但治疗干预措施却未能对预后产生有意义的影响。在这篇综述中,我们将讨论儿科 AKI 的流行病学、迄今为止尝试的治疗策略、针对与 AKI 相关的分子模式的实验性疗法,并强调 AKI 研究和管理所需的方向。儿科需要进行前瞻性试验,以检验诊断工具的有效性,确定最有效的干预点,并强调对 AKI 不同下游效应有效的疗法。
{"title":"Approaches to the Management of Acute Kidney Injury in Children.","authors":"Rajit K Basu, Derek S Wheeler","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Acute kidney injury (AKI) causes increased morbidity in critically ill children and damage to the kidney, a central mediator of homeostasis in the body, affects survival. The incidence of AKI in pediatrics is significant and despite alarming data, therapeutic interventions have failed to effect a meaningful difference in outcomes. In this review, we will discuss the epidemiology of AKI in pediatrics, treatment strategies attempted to date, experimental therapies targeting molecular patterns associated with AKI, and highlight the needed direction of AKI research and management. Prospective trials in pediatrics are needed to test the validity of diagnostic tools, to identify the point of most efficacious intervention, and to underscore the therapies that can be effective in the different downstream effects of AKI.</p>","PeriodicalId":74645,"journal":{"name":"Recent patents on biomarkers","volume":"1 1","pages":"49-59"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3607497/pdf/nihms-300455.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40233292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2011-01-01DOI: 10.2174/2210309011101010049
Rajit K. Basu, D. Wheeler
Acute kidney injury (AKI) causes increased morbidity in critically ill children and damage to the kidney, a central mediator of homeostasis in the body, affects survival. The incidence of AKI in pediatrics is significant and despite alarming data, therapeutic interventions have failed to effect a meaningful difference in outcomes. In this review, we will discuss the epidemiology of AKI in pediatrics, treatment strategies attempted to date, experimental therapies targeting molecular patterns associated with AKI, and highlight the needed direction of AKI research and management. Prospective trials in pediatrics are needed to test the validity of diagnostic tools, to identify the point of most efficacious intervention, and to underscore the therapies that can be effective in the different downstream effects of AKI.
{"title":"Approaches to the Management of Acute Kidney Injury in Children.","authors":"Rajit K. Basu, D. Wheeler","doi":"10.2174/2210309011101010049","DOIUrl":"https://doi.org/10.2174/2210309011101010049","url":null,"abstract":"Acute kidney injury (AKI) causes increased morbidity in critically ill children and damage to the kidney, a central mediator of homeostasis in the body, affects survival. The incidence of AKI in pediatrics is significant and despite alarming data, therapeutic interventions have failed to effect a meaningful difference in outcomes. In this review, we will discuss the epidemiology of AKI in pediatrics, treatment strategies attempted to date, experimental therapies targeting molecular patterns associated with AKI, and highlight the needed direction of AKI research and management. Prospective trials in pediatrics are needed to test the validity of diagnostic tools, to identify the point of most efficacious intervention, and to underscore the therapies that can be effective in the different downstream effects of AKI.","PeriodicalId":74645,"journal":{"name":"Recent patents on biomarkers","volume":"1 1 1","pages":"49-59"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68161364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}